| Literature DB >> 27578526 |
Kelly L Mooney1, Winward Choy1, Sabrin Sidhu1, Panayiotis Pelargos1, Timothy T Bui1, Brittany Voth1, Natalie Barnette1, Isaac Yang2.
Abstract
A transmembrane molecule with several isoforms, CD44 is overexpressed in many tumors and promotes tumor formation through interactions with the tumor microenvironment. CD44 has been implicated in malignant processes including cell motility, tumor growth, and angiogenesis. The role of CD44 has been examined in many cancer types. This paper provides, to our knowledge, the first focused review of the role of CD44 in glioblastoma multiforme (GBM), the most common and fatal of primary brain cancers. We summarize research that describes how CD44 promotes GBM aggressiveness by increasing tumor cell invasion, proliferation and resistance to standard chemoradiation therapy. Effects of CD44 inhibition in GBM are also explored. Clinical trials investigating CD44 targeting in CD44-positive solid tumors are underway, and the evidence presented here suggests that CD44 inhibition in GBM may be a promising therapy.Entities:
Keywords: CD44 protein; CD44v6 antigen; Glioblastoma multiforme
Mesh:
Substances:
Year: 2016 PMID: 27578526 DOI: 10.1016/j.jocn.2016.05.012
Source DB: PubMed Journal: J Clin Neurosci ISSN: 0967-5868 Impact factor: 1.961